Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
29 Juni 2022 - 12:45PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, will hold its second-quarter 2022 sales and earnings
conference call with institutional investors and analysts at 8:00
a.m. ET on Thursday, July 28. During the call, company executives
will provide an overview of Merck’s performance for the quarter and
outlook.
Investors, journalists and the general public may access a live
audio webcast of the call via this weblink. A replay of the
webcast, along with the sales and earnings news release,
supplemental financial disclosures, and slides highlighting the
results, will be available at www.merck.com.
Participants may join the call by dialing 877-692-8955 (USA
Toll-Free) or 234-720-6979. If you are calling from other
countries, visit this weblink. All dial-in participants can use the
access code 1857604. Journalists who wish to ask questions are
requested to contact a member of Merck’s Media Relations team.
About Merck At Merck, known as MSD outside of the United
States and Canada, we are unified around our purpose: We use the
power of leading-edge science to save and improve lives around the
world. For more than 130 years, we have brought hope to humanity
through the development of important medicines and vaccines. We
aspire to be the premier research-intensive biopharmaceutical
company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the
prevention and treatment of diseases in people and animals. We
foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy
future for all people and communities. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, Instagram,
YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway,
N.J., USA This news release of Merck & Co., Inc., Rahway,
N.J., USA (the “company”) includes “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements
are based upon the current beliefs and expectations of the
company’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks
or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2021 and the
company’s other filings with the Securities and Exchange Commission
(SEC) available at the SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220629005168/en/
Media: Johanna Herrmann (617) 216-6029 Melissa Moody (215)
407-3536 Investors: Peter Dannenbaum (908) 740-1037 Steven Graziano
(908) 740-6582
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024